08:59 AM EST, 12/18/2024 (MT Newswires) -- Guardant Health ( GH ) said Wednesday that it is collaborating with German pharmaceutical company Boehringer Ingelheim to seek regulatory approval and commercialize Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer's investigational non-small cell lung cancer drug zongertinib.

Under the collaboration, Guardant said its Guardant360 CDx blood test would provide genomic profiling of tumors to help identify non-small cell lung cancer patients with HER2 mutations who may be eligible for treatment with zongertinib.

Guardant's shares were up 3% in recent premarket activity.